Results 1 to 10 of about 10,242 (284)
Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review [PDF]
Toxins, 2021 Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis.
Emanuela Martina +4 more
doaj +2 more sources
Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications
Toxins, 2021 Over the last few decades, proteins and peptides have become increasingly more common as FDA-approved drugs, despite their inefficient delivery due to their inability to cross the plasma membrane.
Numa Piot +2 more
doaj +3 more sources
Mechanisms of Botulinum Toxin Type A Action on Pain [PDF]
Toxins, 2019 Already a well-established treatment for different autonomic and movement disorders, the use of botulinum toxin type A (BoNT/A) in pain conditions is now continuously expanding. Currently, the only approved use of BoNT/A in relation to pain is the treatment of chronic migraines. However, controlled clinical studies show promising results in neuropathic
Matak, Ivica +3 more
openaire +7 more sources
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]
Cochrane Database of Systematic Reviews, 2016 This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this ...
Duarte, GS +7 more
+9 more sources
PLoS Computational Biology, 2016 Clostridium botulinum produces botulinum neurotoxins (BoNTs), highly potent substances responsible for botulism. Currently, mathematical models of C.
Adaoha E C Ihekwaba +4 more
doaj +2 more sources
Archives of Rehabilitation Research and Clinical Translation, 2021 Objectives: The objectives of this study were to evaluate whether botulinum toxin type A (BoNT-A) treatment for lower limb spasticity leads to patient goal attainment and identify factors associated with positive goal attainment and to assess the effect ...
Subbuh Choudhry, MBBS +4 more
doaj +1 more source
Toxins, 2021 Several studies have investigated the effect of botulinum toxin A (BoNT-A) for managing chronic musculoskeletal pain, bringing contrasting results to the forefront.
Simone Battista +7 more
doaj +1 more source
Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy [PDF]
Anais Brasileiros de Dermatologia, 2014 BACKGROUND: Masseter hypertrophy has been treated with botulinum toxin injections because of esthetic complaints especially in Asians. OBJECTIVES: The goal of the present study was to evaluate the efficacy of abobotulin toxin use in masseter hipertrophy ...
Fernanda Homem de Mello de Souza Klein +4 more
doaj +2 more sources
Botulinum Toxin Type A for Treatment of Masseter Hypertrophy: Volumetric Analysis of Masseter Muscle Reduction over Time [PDF]
Archives of Aesthetic Plastic Surgery, 2016 Background There has been increasing interest in facial contouring procedures throughout Asian countries. As such, botulinum toxin A injections for masseteric hypertrophy have become a common procedure provided to patients who desire non-surgical ...
Edward Ilho Lee +4 more
doaj +1 more source
ABCS Health Sciences, 2022 Introduction: The use of botulinum toxin type A (BTX-A) to correct gummy smile has become popular in recent years. Objective: To evaluate the effects of BTX-A application in the correction of gummy smile 2 and 32 weeks after application.
Carlos Eduardo Alonso Vieira +7 more
doaj +1 more source